ID   PARP1_HUMAN             Reviewed;        1014 AA.
AC   P09874; B1ANJ4; Q8IUZ9;
DT   01-JUL-1989, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 4.
DT   10-MAY-2017, entry version 218.
DE   RecName: Full=Poly [ADP-ribose] polymerase 1;
DE            Short=PARP-1;
DE            EC=2.4.2.30 {ECO:0000269|PubMed:18172500, ECO:0000269|PubMed:28190768};
DE   AltName: Full=ADP-ribosyltransferase diphtheria toxin-like 1;
DE            Short=ARTD1;
DE   AltName: Full=NAD(+) ADP-ribosyltransferase 1;
DE            Short=ADPRT 1;
DE   AltName: Full=Poly[ADP-ribose] synthase 1;
GN   Name=PARP1; Synonyms=ADPRT, PPOL;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Fibroblast;
RX   PubMed=3120710; DOI=10.1016/0006-291X(87)90921-1;
RA   Uchida K., Morita T., Sato T., Ogura T., Yamashita R., Noguchi S.,
RA   Suzuki H., Nyunoya H., Miwa M., Sugimura T.;
RT   "Nucleotide sequence of a full-length cDNA for human fibroblast
RT   poly(ADP-ribose) polymerase.";
RL   Biochem. Biophys. Res. Commun. 148:617-622(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Fibroblast;
RX   PubMed=2824474;
RA   Kurosaki T., Ushiro H., Mitsuuchi Y., Suzuki S., Matsuda M.,
RA   Matsuda Y., Katunuma N., Kangawa K., Matsuo H., Hirose T., Inayama S.,
RA   Shizuta Y.;
RT   "Primary structure of human poly(ADP-ribose) synthetase as deduced
RT   from cDNA sequence.";
RL   J. Biol. Chem. 262:15990-15997(1987).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT ARG-940.
RX   PubMed=2891139; DOI=10.1073/pnas.84.23.8370;
RA   Cherney B.W., McBride O.W., Chen D., Alkhatib H., Bhatia K.,
RA   Hensley P., Smulson M.E.;
RT   "cDNA sequence, protein structure, and chromosomal location of the
RT   human gene for poly(ADP-ribose) polymerase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:8370-8374(1987).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=2513174; DOI=10.1089/dna.1989.8.575;
RA   Auer B., Nagl U., Herzog H., Schneider R., Schweiger M.;
RT   "Human nuclear NAD+ ADP-ribosyltransferase(polymerizing): organization
RT   of the gene.";
RL   DNA 8:575-580(1989).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS THR-188; ILE-334;
RP   TYR-383; ALA-762 AND ARG-940.
RG   NIEHS SNPs program;
RL   Submitted (JUN-2002) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ALA-762.
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-95.
RX   PubMed=2125269; DOI=10.1111/j.1432-1033.1990.tb15647.x;
RA   Yokoyama Y., Kawamoto T., Mitsuuchi Y., Kurosaki T., Toda K.,
RA   Ushiro H., Terashima M., Sumimoto H., Kuribayashi I., Yamamoto Y.,
RA   Maeda T., Ikeda H., Sagara Y., Shizuta Y.;
RT   "Human poly(ADP-ribose) polymerase gene. Cloning of the promoter
RT   region.";
RL   Eur. J. Biochem. 194:521-526(1990).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-40.
RX   PubMed=2108670; DOI=10.1016/0006-291X(90)92082-B;
RA   Ogura T., Nyunoya H., Takahashi-Masutani M., Miwa M., Sugimura T.,
RA   Esumi H.;
RT   "Characterization of a putative promoter region of the human poly(ADP-
RT   ribose) polymerase gene: structural similarity to that of the DNA
RT   polymerase beta gene.";
RL   Biochem. Biophys. Res. Commun. 167:701-710(1990).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-40.
RA   Herzog H., Schneider R., Hirsch-Kauffmann M., Schnitzer D.,
RA   Schweiger M.;
RT   "Human pADPRT is involved in the regulation of its own gene.";
RL   Submitted (JUL-1991) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   PROTEIN SEQUENCE OF 2-10; 35-47; 66-78; 109-119; 183-197; 209-221;
RP   263-282; 453-467; 487-496; 529-548; 552-564; 572-582; 637-654;
RP   668-695; 748-761; 780-796; 803-816 AND 859-903, CLEAVAGE OF INITIATOR
RP   METHIONINE, ACETYLATION AT ALA-2, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RC   TISSUE=Colon carcinoma, and Ovarian carcinoma;
RA   Bienvenut W.V., Zebisch A., Lilla S., von Kriegsheim A., Lempens A.,
RA   Kolch W.;
RL   Submitted (DEC-2008) to UniProtKB.
RN   [13]
RP   PROTEIN SEQUENCE OF 166-177 AND 356-367, INTERACTION WITH EEF1A1 AND
RP   TXK, PHOSPHORYLATION BY TXK, SUBCELLULAR LOCATION, AND FUNCTION AS A
RP   TRANSCRIPTION FACTOR.
RX   PubMed=17177976; DOI=10.1111/j.1365-2249.2006.03249.x;
RA   Maruyama T., Nara K., Yoshikawa H., Suzuki N.;
RT   "Txk, a member of the non-receptor tyrosine kinase of the Tec family,
RT   forms a complex with poly(ADP-ribose) polymerase 1 and elongation
RT   factor 1alpha and regulates interferon-gamma gene transcription in Th1
RT   cells.";
RL   Clin. Exp. Immunol. 147:164-175(2007).
RN   [14]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 381-420 AND 682-710.
RX   PubMed=3121332;
RA   Schneider R., Auer B., Kuhne C., Herzog H., Klocker H.,
RA   Burtscher H.J., Hirsch-Kauffmann M., Wintersberger U., Schweiger M.;
RT   "Isolation of a cDNA clone for human NAD+: protein ADP-
RT   ribosyltransferase.";
RL   Eur. J. Cell Biol. 44:302-307(1987).
RN   [15]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 441-1014.
RX   PubMed=3113420; DOI=10.1016/0006-291X(87)90543-2;
RA   Suzuki H., Uchida K., Shima H., Sato T., Okamoto T., Kimura T.,
RA   Miwa M.;
RT   "Molecular cloning of cDNA for human poly(ADP-ribose) polymerase and
RT   expression of its gene during HL-60 cell differentiation.";
RL   Biochem. Biophys. Res. Commun. 146:403-409(1987).
RN   [16]
RP   ERRATUM.
RA   Suzuki H., Uchida K., Shima H., Sato T., Okamoto T., Kimura T.,
RA   Miwa M.;
RL   Biochem. Biophys. Res. Commun. 148:1549-1550(1987).
RN   [17]
RP   ANALYSIS OF ZINC-FINGERS.
RX   PubMed=2109322; DOI=10.1073/pnas.87.8.2990;
RA   Gradwohl G., Menissier-de Murcia J., Molinete M., Simonin F.,
RA   Koken M.H.M., Hoeijmakers J.H.J., de Murcia G.M.;
RT   "The second zinc-finger domain of poly(ADP-ribose) polymerase
RT   determines specificity for single-stranded breaks in DNA.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:2990-2994(1990).
RN   [18]
RP   ANALYSIS OF ZINC-FINGERS.
RX   PubMed=2123876;
RA   Ikelima M., Noguchi S., Yamashita R., Ogura T., Sugimura T.,
RA   Gill D.M., Miwa M.;
RT   "The zinc fingers of human poly(ADP-ribose) polymerase are
RT   differentially required for the recognition of DNA breaks and nicks
RT   and the consequent enzyme activation. Other structures recognize
RT   intact DNA.";
RL   J. Biol. Chem. 265:21907-21913(1990).
RN   [19]
RP   MUTAGENESIS OF CATALYTIC DOMAIN.
RX   PubMed=2121735;
RA   Simonin F., Menissier-de Murcia J., Poch O., Muller S., Gradwohl G.,
RA   Molinete M., Penning C., Keith G., de Murcia G.M.;
RT   "Expression and site-directed mutagenesis of the catalytic domain of
RT   human poly(ADP-ribose)polymerase in Escherichia coli. Lysine 893 is
RT   critical for activity.";
RL   J. Biol. Chem. 265:19249-19256(1990).
RN   [20]
RP   NUCLEAR LOCALIZATION SIGNAL.
RX   PubMed=1505517;
RA   Schreiber V., Molinete M., Boeuf H., de Murcia G.M.,
RA   Menissier-de Murcia J.;
RT   "The human poly(ADP-ribose) polymerase nuclear localization signal is
RT   a bipartite element functionally separate from DNA binding and
RT   catalytic activity.";
RL   EMBO J. 11:3263-3269(1992).
RN   [21]
RP   MUTAGENESIS OF CATALYTIC DOMAIN.
RX   PubMed=9315851; DOI=10.1021/bi971055p;
RA   Rolli V., O'Farrell M., Menissier-de Murcia J., de Murcia G.M.;
RT   "Random mutagenesis of the poly(ADP-ribose) polymerase catalytic
RT   domain reveals amino acids involved in polymer branching.";
RL   Biochemistry 36:12147-12154(1997).
RN   [22]
RP   INTERACTION WITH POLA1, AND SUBCELLULAR LOCATION.
RX   PubMed=9518481; DOI=10.1093/nar/26.8.1891;
RA   Dantzer F., Nasheuer H.P., Vonesch J.L., de Murcia G.,
RA   Menissier-de Murcia J.;
RT   "Functional association of poly(ADP-ribose) polymerase with DNA
RT   polymerase alpha-primase complex: a link between DNA strand break
RT   detection and DNA replication.";
RL   Nucleic Acids Res. 26:1891-1898(1998).
RN   [23]
RP   PHOSPHORYLATION.
RX   PubMed=10467406; DOI=10.1038/sj.onc.1202823;
RA   Ariumi Y., Masutani M., Copeland T.D., Mimori T., Sugimura T.,
RA   Shimotohno K., Ueda K., Hatanaka M., Noda M.;
RT   "Suppression of the poly(ADP-ribose) polymerase activity by DNA-
RT   dependent protein kinase in vitro.";
RL   Oncogene 18:4616-4625(1999).
RN   [24]
RP   INTERACTION WITH APTX.
RX   PubMed=15044383; DOI=10.1093/hmg/ddh122;
RA   Gueven N., Becherel O.J., Kijas A.W., Chen P., Howe O., Rudolph J.H.,
RA   Gatti R., Date H., Onodera O., Taucher-Scholz G., Lavin M.F.;
RT   "Aprataxin, a novel protein that protects against genotoxic stress.";
RL   Hum. Mol. Genet. 13:1081-1093(2004).
RN   [25]
RP   INTERACTION WITH SRY.
RX   PubMed=16904257; DOI=10.1016/j.mce.2006.06.008;
RA   Li Y., Oh H.J., Lau Y.-F.C.;
RT   "The poly(ADP-ribose) polymerase 1 interacts with Sry and modulates
RT   its biological functions.";
RL   Mol. Cell. Endocrinol. 257:35-46(2006).
RN   [26]
RP   INTERACTION WITH APLF, AND FUNCTION.
RX   PubMed=17396150; DOI=10.1038/sj.emboj.7601663;
RA   Kanno S., Kuzuoka H., Sasao S., Hong Z., Lan L., Nakajima S.,
RA   Yasui A.;
RT   "A novel human AP endonuclease with conserved zinc-finger-like motifs
RT   involved in DNA strand break responses.";
RL   EMBO J. 26:2094-2103(2007).
RN   [27]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-179, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III,
RA   Hurov K.E., Luo J., Bakalarski C.E., Zhao Z., Solimini N.,
RA   Lerenthal Y., Shiloh Y., Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [28]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=18172500; DOI=10.1038/nature06420;
RA   Ahel I., Ahel D., Matsusaka T., Clark A.J., Pines J., Boulton S.J.,
RA   West S.C.;
RT   "Poly(ADP-ribose)-binding zinc finger motifs in DNA repair/checkpoint
RT   proteins.";
RL   Nature 451:81-85(2008).
RN   [29]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-368 AND SER-782, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [30]
RP   FUNCTION.
RX   PubMed=19344625; DOI=10.1016/j.bcp.2009.02.025;
RA   Reinemund J., Seidel K., Steckelings U.M., Zaade D., Klare S.,
RA   Rompe F., Katerbaum M., Schacherl J., Li Y., Menk M., Schefe J.H.,
RA   Goldin-Lang P., Szabo C., Olah G., Unger T., Funke-Kaiser H.;
RT   "Poly(ADP-ribose) polymerase-1 (PARP-1) transcriptionally regulates
RT   angiotensin AT2 receptor (AT2R) and AT2R binding protein (ATBP)
RT   genes.";
RL   Biochem. Pharmacol. 77:1795-1805(2009).
RN   [31]
RP   INTERACTION WITH RNF4.
RX   PubMed=19779455; DOI=10.1038/emboj.2009.279;
RA   Martin N., Schwamborn K., Schreiber V., Werner A., Guillier C.,
RA   Zhang X.D., Bischof O., Seeler J.S., Dejean A.;
RT   "PARP-1 transcriptional activity is regulated by sumoylation upon heat
RT   shock.";
RL   EMBO J. 28:3534-3548(2009).
RN   [32]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-782, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [33]
RP   FUNCTION, POLY-ADP-RIBOSYLATION, AND INTERACTION WITH CHD1L.
RX   PubMed=19661379; DOI=10.1126/science.1177321;
RA   Ahel D., Horejsi Z., Wiechens N., Polo S.E., Garcia-Wilson E.,
RA   Ahel I., Flynn H., Skehel M., West S.C., Jackson S.P., Owen-Hughes T.,
RA   Boulton S.J.;
RT   "Poly(ADP-ribose)-dependent regulation of DNA repair by the chromatin
RT   remodeling enzyme ALC1.";
RL   Science 325:1240-1243(2009).
RN   [34]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-97; LYS-105; LYS-131;
RP   LYS-600 AND LYS-621, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE
RP   SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [35]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-41 AND SER-782, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [36]
RP   NOMENCLATURE.
RX   PubMed=20106667; DOI=10.1016/j.tibs.2009.12.003;
RA   Hottiger M.O., Hassa P.O., Luscher B., Schuler H., Koch-Nolte F.;
RT   "Toward a unified nomenclature for mammalian ADP-
RT   ribosyltransferases.";
RL   Trends Biochem. Sci. 35:208-219(2010).
RN   [37]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [38]
RP   INTERACTION WITH PUM3.
RX   PubMed=21266351; DOI=10.1158/0008-5472.CAN-10-1831;
RA   Chang H.Y., Fan C.C., Chu P.C., Hong B.E., Lee H.J., Chang M.S.;
RT   "hPuf-A/KIAA0020 modulates PARP-1 cleavage upon genotoxic stress.";
RL   Cancer Res. 71:1126-1134(2011).
RN   [39]
RP   INTERACTION WITH SNAI1.
RX   PubMed=21577210; DOI=10.1038/onc.2011.153;
RA   Rodriguez M.I., Gonzalez-Flores A., Dantzer F., Collard J.,
RA   de Herreros A.G., Oliver F.J.;
RT   "Poly(ADP-ribose)-dependent regulation of Snail1 protein stability.";
RL   Oncogene 30:4365-4372(2011).
RN   [40]
RP   INTERACTION WITH RNF146, AND SUBCELLULAR LOCATION.
RX   PubMed=21799911; DOI=10.1371/journal.pone.0022595;
RA   Callow M.G., Tran H., Phu L., Lau T., Lee J., Sandoval W.N., Liu P.S.,
RA   Bheddah S., Tao J., Lill J.R., Hongo J.A., Davis D., Kirkpatrick D.S.,
RA   Polakis P., Costa M.;
RT   "Ubiquitin ligase RNF146 regulates tankyrase and Axin to promote Wnt
RT   signaling.";
RL   PLoS ONE 6:E22595-E22595(2011).
RN   [41]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-782, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [42]
RP   INTERACTION WITH ZNF423.
RX   PubMed=22863007; DOI=10.1016/j.cell.2012.06.028;
RA   Chaki M., Airik R., Ghosh A.K., Giles R.H., Chen R., Slaats G.G.,
RA   Wang H., Hurd T.W., Zhou W., Cluckey A., Gee H.Y., Ramaswami G.,
RA   Hong C.J., Hamilton B.A., Cervenka I., Ganji R.S., Bryja V.,
RA   Arts H.H., van Reeuwijk J., Oud M.M., Letteboer S.J., Roepman R.,
RA   Husson H., Ibraghimov-Beskrovnaya O., Yasunaga T., Walz G., Eley L.,
RA   Sayer J.A., Schermer B., Liebau M.C., Benzing T., Le Corre S.,
RA   Drummond I., Janssen S., Allen S.J., Natarajan S., O'Toole J.F.,
RA   Attanasio M., Saunier S., Antignac C., Koenekoop R.K., Ren H.,
RA   Lopez I., Nayir A., Stoetzel C., Dollfus H., Massoudi R.,
RA   Gleeson J.G., Andreoli S.P., Doherty D.G., Lindstrad A., Golzio C.,
RA   Katsanis N., Pape L., Abboud E.B., Al-Rajhi A.A., Lewis R.A.,
RA   Omran H., Lee E.Y., Wang S., Sekiguchi J.M., Saunders R.,
RA   Johnson C.A., Garner E., Vanselow K., Andersen J.S., Shlomai J.,
RA   Nurnberg G., Nurnberg P., Levy S., Smogorzewska A., Otto E.A.,
RA   Hildebrandt F.;
RT   "Exome capture reveals ZNF423 and CEP164 mutations, linking renal
RT   ciliopathies to DNA damage response signaling.";
RL   Cell 150:533-548(2012).
RN   [43]
RP   SUBCELLULAR LOCATION [LARGE SCALE ANALYSIS].
RX   PubMed=22002106; DOI=10.1074/mcp.M111.013680;
RA   Ahmad Y., Boisvert F.M., Lundberg E., Uhlen M., Lamond A.I.;
RT   "Systematic analysis of protein pools, isoforms, and modifications
RT   affecting turnover and subcellular localization.";
RL   Mol. Cell. Proteomics 11:M111.013680.01-M111.013680.15(2012).
RN   [44]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [45]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-41; SER-177; SER-179;
RP   SER-185; SER-274; SER-277; SER-782 AND SER-786, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [46]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH PARP9.
RX   PubMed=23230272; DOI=10.1128/MCB.00990-12;
RA   Yan Q., Xu R., Zhu L., Cheng X., Wang Z., Manis J., Shipp M.A.;
RT   "BAL1 and its partner E3 ligase, BBAP, link Poly(ADP-ribose)
RT   activation, ubiquitylation, and double-strand DNA repair independent
RT   of ATM, MDC1, and RNF8.";
RL   Mol. Cell. Biol. 33:845-857(2013).
RN   [47]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-364, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [48]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-486; LYS-512 AND LYS-748,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25218447; DOI=10.1038/nsmb.2890;
RA   Hendriks I.A., D'Souza R.C., Yang B., Verlaan-de Vries M., Mann M.,
RA   Vertegaal A.C.;
RT   "Uncovering global SUMOylation signaling networks in a site-specific
RT   manner.";
RL   Nat. Struct. Mol. Biol. 21:927-936(2014).
RN   [49]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-203; LYS-486 AND LYS-748,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25114211; DOI=10.1073/pnas.1413825111;
RA   Impens F., Radoshevich L., Cossart P., Ribet D.;
RT   "Mapping of SUMO sites and analysis of SUMOylation changes induced by
RT   external stimuli.";
RL   Proc. Natl. Acad. Sci. U.S.A. 111:12432-12437(2014).
RN   [50]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-203; LYS-467; LYS-486 AND
RP   LYS-512, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=25772364; DOI=10.1016/j.celrep.2015.02.033;
RA   Hendriks I.A., Treffers L.W., Verlaan-de Vries M., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "SUMO-2 orchestrates chromatin modifiers in response to DNA damage.";
RL   Cell Rep. 10:1778-1791(2015).
RN   [51]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-512, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25755297; DOI=10.1074/mcp.O114.044792;
RA   Xiao Z., Chang J.G., Hendriks I.A., Sigurdsson J.O., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "System-wide analysis of SUMOylation dynamics in response to
RT   replication stress reveals novel small ubiquitin-like modified target
RT   proteins and acceptor lysines relevant for genome stability.";
RL   Mol. Cell. Proteomics 14:1419-1434(2015).
RN   [52]
RP   FUNCTION, AND INTERACTION WITH HPF1.
RX   PubMed=27067600; DOI=10.1016/j.molcel.2016.03.008;
RA   Gibbs-Seymour I., Fontana P., Rack J.G., Ahel I.;
RT   "HPF1/C4orf27 is a PARP-1-interacting protein that regulates PARP-1
RT   ADP-ribosylation activity.";
RL   Mol. Cell 62:432-442(2016).
RN   [53]
RP   FUNCTION.
RX   PubMed=27257257; DOI=10.1126/science.aad9335;
RA   Wright R.H., Lioutas A., Le Dily F., Soronellas D., Pohl A., Bonet J.,
RA   Nacht A.S., Samino S., Font-Mateu J., Vicent G.P., Wierer M.,
RA   Trabado M.A., Schelhorn C., Carolis C., Macias M.J., Yanes O.,
RA   Oliva B., Beato M.;
RT   "ADP-ribose-derived nuclear ATP synthesis by NUDIX5 is required for
RT   chromatin remodeling.";
RL   Science 352:1221-1225(2016).
RN   [54]
RP   FUNCTION, CATALYTIC ACTIVITY, INTERACTION WITH HPF1, ADP-RIBOSYLATION
RP   AT SER-499; SER-507 AND SER-519, AND MUTAGENESIS OF SER-499; SER-507
RP   AND SER-519.
RX   PubMed=28190768; DOI=10.1016/j.molcel.2017.01.003;
RA   Bonfiglio J.J., Fontana P., Zhang Q., Colby T., Gibbs-Seymour I.,
RA   Atanassov I., Bartlett E., Zaja R., Ahel I., Matic I.;
RT   "Serine ADP-ribosylation depends on HPF1.";
RL   Mol. Cell 0:0-0(2017).
RN   [55]
RP   STRUCTURE BY NMR OF 1-93 AND 385-643.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the first ZF-PARP domain, of the BRCT domain
RT   and of the WGR domain of human poly(ADP-ribose)polymerase-1.";
RL   Submitted (APR-2007) to the PDB data bank.
RN   [56]
RP   VARIANT [LARGE SCALE ANALYSIS] VAL-488.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
CC   -!- FUNCTION: Involved in the base excision repair (BER) pathway, by
CC       catalyzing the poly(ADP-ribosyl)ation of a limited number of
CC       acceptor proteins involved in chromatin architecture and in DNA
CC       metabolism. This modification follows DNA damages and appears as
CC       an obligatory step in a detection/signaling pathway leading to the
CC       reparation of DNA strand breaks (PubMed:17177976, PubMed:18172500,
CC       PubMed:19344625, PubMed:19661379, PubMed:23230272). Mediates the
CC       poly(ADP-ribosyl)ation of APLF and CHFR (PubMed:17396150).
CC       Positively regulates the transcription of MTUS1 and negatively
CC       regulates the transcription of MTUS2/TIP150. With EEF1A1 and TXK,
CC       forms a complex that acts as a T-helper 1 (Th1) cell-specific
CC       transcription factor and binds the promoter of IFN-gamma to
CC       directly regulate its transcription, and is thus involved
CC       importantly in Th1 cytokine production (PubMed:17177976). Required
CC       for PARP9 and DTX3L recruitment to DNA damage sites
CC       (PubMed:23230272). PARP1-dependent PARP9-DTX3L-mediated
CC       ubiquitination promotes the rapid and specific recruitment of
CC       53BP1/TP53BP1, UIMC1/RAP80, and BRCA1 to DNA damage sites
CC       (PubMed:23230272). Mediates serine ADP-ribosylation of target
CC       proteins following interaction with HPF1; HPF1 conferring serine
CC       specificity (PubMed:28190768). Mediates the poly(ADP-ribosyl)ation
CC       of histones in a HPF1-dependent manner (PubMed:27067600). Involved
CC       in the synthesis of ATP in the nucleus, together with NMNAT1, PARG
CC       and NUDT5 (PubMed:27257257). Nuclear ATP generation is required
CC       for extensive chromatin remodeling events that are energy-
CC       consuming (PubMed:27257257). {ECO:0000269|PubMed:17177976,
CC       ECO:0000269|PubMed:17396150, ECO:0000269|PubMed:18172500,
CC       ECO:0000269|PubMed:19344625, ECO:0000269|PubMed:19661379,
CC       ECO:0000269|PubMed:23230272, ECO:0000269|PubMed:27067600,
CC       ECO:0000269|PubMed:27257257, ECO:0000269|PubMed:28190768}.
CC   -!- CATALYTIC ACTIVITY: NAD(+) + (ADP-D-ribosyl)(n)-acceptor =
CC       nicotinamide + (ADP-D-ribosyl)(n+1)-acceptor.
CC       {ECO:0000255|PROSITE-ProRule:PRU00397,
CC       ECO:0000269|PubMed:18172500, ECO:0000269|PubMed:28190768}.
CC   -!- SUBUNIT: Component of a base excision repair (BER) complex,
CC       containing at least XRCC1, PARP2, POLB and LRIG3. Homo- and
CC       heterodimer with PARP2. Interacts with APTX (PubMed:15044383).
CC       Interacts with PARP3. Interacts with SRY (PubMed:16904257). The
CC       SWAP complex consists of NPM1, NCL, PARP1 and SWAP70. Interacts
CC       with TIAM2 (By similarity). Interacts (when poly-ADP-ribosylated)
CC       with CHD1L (PubMed:19661379). Interacts with the DNA polymerase
CC       alpha catalytic subunit POLA1; this interaction functions as part
CC       of the control of replication fork progression (PubMed:9518481).
CC       Interacts with EEF1A1 and TXK (PubMed:17177976). Interacts with
CC       RNF4 (PubMed:19779455). Interacts with RNF146 (PubMed:21799911).
CC       Interacts with ZNF423 (PubMed:22863007). Interacts with SNAI1 (via
CC       zinc fingers); the interaction requires SNAI1 to be poly-ADP-
CC       ribosylated and non-phosphorylated (active) by GSK3B
CC       (PubMed:21577210). Interacts (when poly-ADP-ribosylated) with
CC       PARP9 (PubMed:23230272). Interacts with NR4A3; activates PARP1 by
CC       improving acetylation of PARP1 and suppressing the interaction
CC       between PARP1 and SIRT1 (By similarity). Interacts (via catalytic
CC       domain) with PUM3; the interaction inhibits the poly(ADP-
CC       ribosyl)ation activity of PARP1 and the degradation of PARP1 by
CC       CASP3 following genotoxic stress (PubMed:21266351). Interacts (via
CC       the PARP catalytic domain) with HPF1 (PubMed:27067600,
CC       PubMed:28190768). {ECO:0000250|UniProtKB:P27008,
CC       ECO:0000269|PubMed:15044383, ECO:0000269|PubMed:16904257,
CC       ECO:0000269|PubMed:17177976, ECO:0000269|PubMed:17396150,
CC       ECO:0000269|PubMed:19661379, ECO:0000269|PubMed:19779455,
CC       ECO:0000269|PubMed:21266351, ECO:0000269|PubMed:21577210,
CC       ECO:0000269|PubMed:21799911, ECO:0000269|PubMed:22863007,
CC       ECO:0000269|PubMed:23230272, ECO:0000269|PubMed:27067600,
CC       ECO:0000269|PubMed:28190768, ECO:0000269|PubMed:9518481}.
CC   -!- INTERACTION:
CC       Self; NbExp=3; IntAct=EBI-355676, EBI-355676;
CC       Q8IW19:APLF; NbExp=3; IntAct=EBI-355676, EBI-1256044;
CC       Q7Z2E3:APTX; NbExp=8; IntAct=EBI-355676, EBI-847814;
CC       P49715:CEBPA; NbExp=2; IntAct=EBI-355676, EBI-1172054;
CC       P26358:DNMT1; NbExp=6; IntAct=EBI-355676, EBI-719459;
CC       Q01094:E2F1; NbExp=2; IntAct=EBI-355676, EBI-448924;
CC       P11308:ERG; NbExp=7; IntAct=EBI-355676, EBI-79704;
CC       Q13007:IL24; NbExp=2; IntAct=EBI-355676, EBI-3915542;
CC       Q9Y530:OARD1; NbExp=5; IntAct=EBI-355676, EBI-8502288;
CC       Q8N2W9:PIAS4; NbExp=5; IntAct=EBI-355676, EBI-473160;
CC       O95863:SNAI1; NbExp=10; IntAct=EBI-355676, EBI-1045459;
CC       Q02085:Snai1 (xeno); NbExp=3; IntAct=EBI-355676, EBI-6049807;
CC       P63165:SUMO1; NbExp=2; IntAct=EBI-355676, EBI-80140;
CC       P04637:TP53; NbExp=3; IntAct=EBI-355676, EBI-366083;
CC       P0CG48:UBC; NbExp=2; IntAct=EBI-355676, EBI-3390054;
CC       Q14191:WRN; NbExp=8; IntAct=EBI-355676, EBI-368417;
CC       P18887:XRCC1; NbExp=6; IntAct=EBI-355676, EBI-947466;
CC       Q2M1K9:ZNF423; NbExp=2; IntAct=EBI-355676, EBI-950016;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:17177976,
CC       ECO:0000269|PubMed:21799911, ECO:0000269|PubMed:23230272}.
CC       Nucleus, nucleolus {ECO:0000269|PubMed:9518481}. Note=Localizes at
CC       sites of DNA damage. {ECO:0000269|PubMed:23230272}.
CC   -!- PTM: Phosphorylated by PRKDC and TXK.
CC       {ECO:0000269|PubMed:10467406, ECO:0000269|PubMed:17177976}.
CC   -!- PTM: Poly-ADP-ribosylated by PARP2; poly-ADP-ribosylation mediates
CC       the recruitment of CHD1L to DNA damage sites (PubMed:19661379).
CC       ADP-ribosylated on serine by autocatalysis; serine ADP-
CC       ribosylation takes place following interaction with HPF1
CC       (PubMed:28190768). {ECO:0000269|PubMed:19661379,
CC       ECO:0000269|PubMed:28190768}.
CC   -!- PTM: S-nitrosylated, leading to inhibit transcription regulation
CC       activity. {ECO:0000250|UniProtKB:P11103}.
CC   -!- MISCELLANEOUS: The ADP-D-ribosyl group of NAD(+) is transferred to
CC       an acceptor carboxyl group on a histone or the enzyme itself, and
CC       further ADP-ribosyl groups are transferred to the 2'-position of
CC       the terminal adenosine moiety, building up a polymer with an
CC       average chain length of 20-30 units.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/adprt/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M18112; AAA60137.1; -; mRNA.
DR   EMBL; J03473; AAB59447.1; -; mRNA.
DR   EMBL; M32721; AAA60155.1; -; mRNA.
DR   EMBL; M29786; AAA51663.1; -; Genomic_DNA.
DR   EMBL; M29545; AAA51663.1; JOINED; Genomic_DNA.
DR   EMBL; M29766; AAA51663.1; JOINED; Genomic_DNA.
DR   EMBL; M29767; AAA51663.1; JOINED; Genomic_DNA.
DR   EMBL; M29768; AAA51663.1; JOINED; Genomic_DNA.
DR   EMBL; M29769; AAA51663.1; JOINED; Genomic_DNA.
DR   EMBL; M29770; AAA51663.1; JOINED; Genomic_DNA.
DR   EMBL; M29771; AAA51663.1; JOINED; Genomic_DNA.
DR   EMBL; M29772; AAA51663.1; JOINED; Genomic_DNA.
DR   EMBL; M29773; AAA51663.1; JOINED; Genomic_DNA.
DR   EMBL; M29774; AAA51663.1; JOINED; Genomic_DNA.
DR   EMBL; M29775; AAA51663.1; JOINED; Genomic_DNA.
DR   EMBL; M29776; AAA51663.1; JOINED; Genomic_DNA.
DR   EMBL; M29777; AAA51663.1; JOINED; Genomic_DNA.
DR   EMBL; M29778; AAA51663.1; JOINED; Genomic_DNA.
DR   EMBL; M29779; AAA51663.1; JOINED; Genomic_DNA.
DR   EMBL; M29780; AAA51663.1; JOINED; Genomic_DNA.
DR   EMBL; M29781; AAA51663.1; JOINED; Genomic_DNA.
DR   EMBL; M29783; AAA51663.1; JOINED; Genomic_DNA.
DR   EMBL; M29784; AAA51663.1; JOINED; Genomic_DNA.
DR   EMBL; M29785; AAA51663.1; JOINED; Genomic_DNA.
DR   EMBL; M29544; AAA51663.1; JOINED; Genomic_DNA.
DR   EMBL; M29782; AAA51663.1; JOINED; Genomic_DNA.
DR   EMBL; AF524947; AAM75364.1; -; Genomic_DNA.
DR   EMBL; AL359704; CAH70215.1; -; Genomic_DNA.
DR   EMBL; AL359742; CAH70215.1; JOINED; Genomic_DNA.
DR   EMBL; AL359742; CAI12102.1; -; Genomic_DNA.
DR   EMBL; AL359704; CAI12102.1; JOINED; Genomic_DNA.
DR   EMBL; CH471098; EAW69783.1; -; Genomic_DNA.
DR   EMBL; BC037545; AAH37545.1; -; mRNA.
DR   EMBL; X56140; CAA39606.1; -; Genomic_DNA.
DR   EMBL; X56141; CAA39606.1; JOINED; Genomic_DNA.
DR   EMBL; X16674; CAA34663.1; -; Genomic_DNA.
DR   EMBL; M60436; AAA60000.1; -; Genomic_DNA.
DR   EMBL; M17081; AAA51599.1; ALT_SEQ; mRNA.
DR   CCDS; CCDS1554.1; -.
DR   PIR; A29725; A29725.
DR   RefSeq; NP_001609.2; NM_001618.3.
DR   UniGene; Hs.177766; -.
DR   PDB; 1UK0; X-ray; 3.00 A; A/B=662-1011.
DR   PDB; 1UK1; X-ray; 3.00 A; A/B=662-1011.
DR   PDB; 1WOK; X-ray; 3.00 A; A/B/C/D=662-1011.
DR   PDB; 2COK; NMR; -; A=387-486.
DR   PDB; 2CR9; NMR; -; A=518-643.
DR   PDB; 2CS2; NMR; -; A=103-223.
DR   PDB; 2DMJ; NMR; -; A=1-93.
DR   PDB; 2JVN; NMR; -; A=233-358.
DR   PDB; 2L30; NMR; -; A=1-108.
DR   PDB; 2L31; NMR; -; A=103-214.
DR   PDB; 2N8A; NMR; -; A=1-214.
DR   PDB; 2RCW; X-ray; 2.80 A; A=662-1011.
DR   PDB; 2RD6; X-ray; 2.30 A; A=662-1011.
DR   PDB; 2RIQ; X-ray; 1.70 A; A=216-366.
DR   PDB; 3GJW; X-ray; 2.30 A; A=662-1011.
DR   PDB; 3GN7; X-ray; 2.50 A; A=662-1011.
DR   PDB; 3L3L; X-ray; 2.50 A; A=662-1011.
DR   PDB; 3L3M; X-ray; 2.50 A; A=662-1011.
DR   PDB; 3OD8; X-ray; 2.40 A; A/B/C/D/E/F/G/H=2-96.
DR   PDB; 3ODA; X-ray; 2.64 A; A/B/C/D/E/F/G/H=2-96.
DR   PDB; 3ODC; X-ray; 2.80 A; A/B=105-206.
DR   PDB; 3ODE; X-ray; 2.95 A; A/B=105-206.
DR   PDB; 4AV1; X-ray; 3.10 A; A/B/C/D=5-202.
DR   PDB; 4DQY; X-ray; 3.25 A; A/D=1-96, B/E=216-366, C/F=518-1014.
DR   PDB; 4GV7; X-ray; 2.89 A; A/B/C/D=662-1011.
DR   PDB; 4HHY; X-ray; 2.36 A; A/B/C/D=660-1011.
DR   PDB; 4HHZ; X-ray; 2.72 A; A/B/C/D=660-1011.
DR   PDB; 4L6S; X-ray; 2.20 A; A/B=662-1011.
DR   PDB; 4OPX; X-ray; 3.31 A; A/D=1-97, A/D=207-366, C/F=518-1014.
DR   PDB; 4OQA; X-ray; 3.65 A; A/D=1-97, A/D=207-366, C/F=518-1014.
DR   PDB; 4OQB; X-ray; 3.36 A; A/D=1-97, A/D=207-366, C/F=518-1014.
DR   PDB; 4PJT; X-ray; 2.35 A; A/B/C/D=662-1011.
DR   PDB; 4R5W; X-ray; 2.84 A; A/B=662-1011.
DR   PDB; 4R6E; X-ray; 2.20 A; A/B/C/D=662-1011.
DR   PDB; 4RV6; X-ray; 3.19 A; A/B/C/D=662-1011.
DR   PDB; 4UND; X-ray; 2.20 A; A/B=662-1011.
DR   PDB; 4UXB; X-ray; 3.22 A; A/B=662-1011.
DR   PDB; 4XHU; X-ray; 2.09 A; A/C=661-1014.
DR   PDB; 4ZZZ; X-ray; 1.90 A; A/B=655-1014.
DR   PDB; 5A00; X-ray; 2.75 A; A=655-1014.
DR   PDB; 5DS3; X-ray; 2.60 A; A=788-1012.
DR   PDB; 5HA9; X-ray; 4.01 A; A/B=662-1011.
DR   PDB; 5KPN; X-ray; 2.30 A; A/B=662-1011.
DR   PDB; 5KPO; X-ray; 2.65 A; A/B=662-1011.
DR   PDB; 5KPP; X-ray; 2.33 A; A/B=662-1011.
DR   PDB; 5KPQ; X-ray; 2.55 A; A/B=662-1011.
DR   PDB; 5WRQ; X-ray; 2.65 A; A/B=662-1011.
DR   PDB; 5WRY; X-ray; 2.30 A; A/B=662-1011.
DR   PDB; 5WRZ; X-ray; 2.20 A; A/B=662-1011.
DR   PDB; 5WS0; X-ray; 2.60 A; A/B=662-1011.
DR   PDB; 5WS1; X-ray; 1.90 A; A/B=662-1011.
DR   PDB; 5WTC; X-ray; 2.20 A; A/B=662-1011.
DR   PDBsum; 1UK0; -.
DR   PDBsum; 1UK1; -.
DR   PDBsum; 1WOK; -.
DR   PDBsum; 2COK; -.
DR   PDBsum; 2CR9; -.
DR   PDBsum; 2CS2; -.
DR   PDBsum; 2DMJ; -.
DR   PDBsum; 2JVN; -.
DR   PDBsum; 2L30; -.
DR   PDBsum; 2L31; -.
DR   PDBsum; 2N8A; -.
DR   PDBsum; 2RCW; -.
DR   PDBsum; 2RD6; -.
DR   PDBsum; 2RIQ; -.
DR   PDBsum; 3GJW; -.
DR   PDBsum; 3GN7; -.
DR   PDBsum; 3L3L; -.
DR   PDBsum; 3L3M; -.
DR   PDBsum; 3OD8; -.
DR   PDBsum; 3ODA; -.
DR   PDBsum; 3ODC; -.
DR   PDBsum; 3ODE; -.
DR   PDBsum; 4AV1; -.
DR   PDBsum; 4DQY; -.
DR   PDBsum; 4GV7; -.
DR   PDBsum; 4HHY; -.
DR   PDBsum; 4HHZ; -.
DR   PDBsum; 4L6S; -.
DR   PDBsum; 4OPX; -.
DR   PDBsum; 4OQA; -.
DR   PDBsum; 4OQB; -.
DR   PDBsum; 4PJT; -.
DR   PDBsum; 4R5W; -.
DR   PDBsum; 4R6E; -.
DR   PDBsum; 4RV6; -.
DR   PDBsum; 4UND; -.
DR   PDBsum; 4UXB; -.
DR   PDBsum; 4XHU; -.
DR   PDBsum; 4ZZZ; -.
DR   PDBsum; 5A00; -.
DR   PDBsum; 5DS3; -.
DR   PDBsum; 5HA9; -.
DR   PDBsum; 5KPN; -.
DR   PDBsum; 5KPO; -.
DR   PDBsum; 5KPP; -.
DR   PDBsum; 5KPQ; -.
DR   PDBsum; 5WRQ; -.
DR   PDBsum; 5WRY; -.
DR   PDBsum; 5WRZ; -.
DR   PDBsum; 5WS0; -.
DR   PDBsum; 5WS1; -.
DR   PDBsum; 5WTC; -.
DR   ProteinModelPortal; P09874; -.
DR   SMR; P09874; -.
DR   BioGrid; 106652; 257.
DR   DIP; DIP-38N; -.
DR   IntAct; P09874; 95.
DR   MINT; MINT-104344; -.
DR   STRING; 9606.ENSP00000355759; -.
DR   BindingDB; P09874; -.
DR   ChEMBL; CHEMBL3105; -.
DR   DrugBank; DB04010; 2-(3'-Methoxyphenyl) Benzimidazole-4-Carboxamide.
DR   DrugBank; DB03509; 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide.
DR   DrugBank; DB03073; 3-Methoxybenzamide.
DR   DrugBank; DB02498; Carba-Nicotinamide-Adenine-Dinucleotide.
DR   DrugBank; DB02701; Nicotinamide.
DR   DrugBank; DB02690; NU1025.
DR   DrugBank; DB09074; Olaparib.
DR   DrugBank; DB07330; trans-4-(7-carbamoyl-1H-benzimidazol-2-yl)-1-propylpiperidinium.
DR   DrugBank; DB07232; Veliparib.
DR   GuidetoPHARMACOLOGY; 2771; -.
DR   iPTMnet; P09874; -.
DR   PhosphoSitePlus; P09874; -.
DR   SwissPalm; P09874; -.
DR   BioMuta; PARP1; -.
DR   DMDM; 130781; -.
DR   SWISS-2DPAGE; P09874; -.
DR   EPD; P09874; -.
DR   MaxQB; P09874; -.
DR   PaxDb; P09874; -.
DR   PeptideAtlas; P09874; -.
DR   PRIDE; P09874; -.
DR   DNASU; 142; -.
DR   Ensembl; ENST00000366794; ENSP00000355759; ENSG00000143799.
DR   GeneID; 142; -.
DR   KEGG; hsa:142; -.
DR   UCSC; uc001hqd.5; human.
DR   CTD; 142; -.
DR   DisGeNET; 142; -.
DR   GeneCards; PARP1; -.
DR   H-InvDB; HIX0023551; -.
DR   HGNC; HGNC:270; PARP1.
DR   HPA; CAB000147; -.
DR   HPA; CAB003839; -.
DR   HPA; CAB003840; -.
DR   HPA; CAB075726; -.
DR   HPA; CAB075727; -.
DR   HPA; HPA045168; -.
DR   MIM; 173870; gene.
DR   neXtProt; NX_P09874; -.
DR   OpenTargets; ENSG00000143799; -.
DR   PharmGKB; PA32; -.
DR   eggNOG; KOG1037; Eukaryota.
DR   eggNOG; ENOG410XP18; LUCA.
DR   GeneTree; ENSGT00390000017341; -.
DR   HOGENOM; HOG000030402; -.
DR   HOVERGEN; HBG053513; -.
DR   InParanoid; P09874; -.
DR   KO; K10798; -.
DR   OMA; EIEVAYN; -.
DR   OrthoDB; EOG091G13H1; -.
DR   PhylomeDB; P09874; -.
DR   TreeFam; TF316616; -.
DR   BRENDA; 2.4.2.30; 2681.
DR   Reactome; R-HSA-110362; POLB-Dependent Long Patch Base Excision Repair.
DR   Reactome; R-HSA-2173795; Downregulation of SMAD2/3:SMAD4 transcriptional activity.
DR   Reactome; R-HSA-3108214; SUMOylation of DNA damage response and repair proteins.
DR   Reactome; R-HSA-5685939; HDR through MMEJ (alt-NHEJ).
DR   Reactome; R-HSA-5696394; DNA Damage Recognition in GG-NER.
DR   Reactome; R-HSA-5696395; Formation of Incision Complex in GG-NER.
DR   Reactome; R-HSA-5696400; Dual Incision in GG-NER.
DR   SignaLink; P09874; -.
DR   SIGNOR; P09874; -.
DR   ChiTaRS; PARP1; human.
DR   EvolutionaryTrace; P09874; -.
DR   GeneWiki; PARP1; -.
DR   GenomeRNAi; 142; -.
DR   PMAP-CutDB; P09874; -.
DR   PRO; PR:P09874; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; ENSG00000143799; -.
DR   CleanEx; HS_PARP1; -.
DR   ExpressionAtlas; P09874; baseline and differential.
DR   Genevisible; P09874; HS.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0005739; C:mitochondrion; IDA:MGI.
DR   GO; GO:0000784; C:nuclear chromosome, telomeric region; IDA:BHF-UCL.
DR   GO; GO:0005635; C:nuclear envelope; IDA:UniProtKB.
DR   GO; GO:0005730; C:nucleolus; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0043234; C:protein complex; IDA:CAFA.
DR   GO; GO:0032993; C:protein-DNA complex; IDA:CAFA.
DR   GO; GO:0005667; C:transcription factor complex; IDA:BHF-UCL.
DR   GO; GO:0003677; F:DNA binding; TAS:ProtInc.
DR   GO; GO:0003910; F:DNA ligase (ATP) activity; IBA:GO_Central.
DR   GO; GO:0019899; F:enzyme binding; IPI:UniProtKB.
DR   GO; GO:0030331; F:estrogen receptor binding; IEA:Ensembl.
DR   GO; GO:0042826; F:histone deacetylase binding; IEA:Ensembl.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0051287; F:NAD binding; IEA:Ensembl.
DR   GO; GO:0003950; F:NAD+ ADP-ribosyltransferase activity; IDA:UniProtKB.
DR   GO; GO:1990404; F:protein ADP-ribosylase activity; IDA:UniProtKB.
DR   GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB.
DR   GO; GO:0047485; F:protein N-terminus binding; IPI:UniProtKB.
DR   GO; GO:0070412; F:R-SMAD binding; IEA:Ensembl.
DR   GO; GO:0003723; F:RNA binding; IDA:UniProtKB.
DR   GO; GO:0008134; F:transcription factor binding; IPI:BHF-UCL.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:1990966; P:ATP generation from poly-ADP-D-ribose; IDA:UniProtKB.
DR   GO; GO:1904646; P:cellular response to beta-amyloid; IEA:Ensembl.
DR   GO; GO:0006974; P:cellular response to DNA damage stimulus; IMP:UniProtKB.
DR   GO; GO:0032869; P:cellular response to insulin stimulus; IDA:BHF-UCL.
DR   GO; GO:0034599; P:cellular response to oxidative stress; IMP:MGI.
DR   GO; GO:0071294; P:cellular response to zinc ion; IEA:Ensembl.
DR   GO; GO:0042769; P:DNA damage response, detection of DNA damage; IEA:Ensembl.
DR   GO; GO:0051103; P:DNA ligation involved in DNA repair; IBA:GO_Central.
DR   GO; GO:0006281; P:DNA repair; TAS:UniProtKB.
DR   GO; GO:0006302; P:double-strand break repair; IMP:UniProtKB.
DR   GO; GO:0000724; P:double-strand break repair via homologous recombination; TAS:Reactome.
DR   GO; GO:0070911; P:global genome nucleotide-excision repair; TAS:Reactome.
DR   GO; GO:0006273; P:lagging strand elongation; IBA:GO_Central.
DR   GO; GO:0030225; P:macrophage differentiation; TAS:UniProtKB.
DR   GO; GO:0032042; P:mitochondrial DNA metabolic process; IMP:MGI.
DR   GO; GO:0043504; P:mitochondrial DNA repair; IMP:MGI.
DR   GO; GO:0007005; P:mitochondrion organization; IMP:MGI.
DR   GO; GO:2001170; P:negative regulation of ATP biosynthetic process; IMP:ParkinsonsUK-UCL.
DR   GO; GO:1904357; P:negative regulation of telomere maintenance via telomere lengthening; ISS:BHF-UCL.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; TAS:Reactome.
DR   GO; GO:0000715; P:nucleotide-excision repair, DNA damage recognition; TAS:Reactome.
DR   GO; GO:0000717; P:nucleotide-excision repair, DNA duplex unwinding; TAS:Reactome.
DR   GO; GO:0033683; P:nucleotide-excision repair, DNA incision; TAS:Reactome.
DR   GO; GO:0006295; P:nucleotide-excision repair, DNA incision, 3'-to lesion; TAS:Reactome.
DR   GO; GO:0006296; P:nucleotide-excision repair, DNA incision, 5'-to lesion; TAS:Reactome.
DR   GO; GO:0006294; P:nucleotide-excision repair, preincision complex assembly; TAS:Reactome.
DR   GO; GO:0006293; P:nucleotide-excision repair, preincision complex stabilization; TAS:Reactome.
DR   GO; GO:0018312; P:peptidyl-serine ADP-ribosylation; IDA:UniProtKB.
DR   GO; GO:0010613; P:positive regulation of cardiac muscle hypertrophy; ISS:UniProtKB.
DR   GO; GO:0033148; P:positive regulation of intracellular estrogen receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0051901; P:positive regulation of mitochondrial depolarization; IEA:Ensembl.
DR   GO; GO:1904762; P:positive regulation of myofibroblast differentiation; IEA:Ensembl.
DR   GO; GO:1901216; P:positive regulation of neuron death; IEA:Ensembl.
DR   GO; GO:0060391; P:positive regulation of SMAD protein import into nucleus; IEA:Ensembl.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IEA:Ensembl.
DR   GO; GO:2000679; P:positive regulation of transcription regulatory region DNA binding; IEA:Ensembl.
DR   GO; GO:0006471; P:protein ADP-ribosylation; IDA:UniProtKB.
DR   GO; GO:0016540; P:protein autoprocessing; IEA:Ensembl.
DR   GO; GO:0036211; P:protein modification process; IMP:MGI.
DR   GO; GO:0070212; P:protein poly-ADP-ribosylation; IDA:UniProtKB.
DR   GO; GO:0050790; P:regulation of catalytic activity; IDA:BHF-UCL.
DR   GO; GO:1903827; P:regulation of cellular protein localization; IMP:MGI.
DR   GO; GO:0044030; P:regulation of DNA methylation; IEA:Ensembl.
DR   GO; GO:1903376; P:regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathway; IEA:Ensembl.
DR   GO; GO:0010990; P:regulation of SMAD protein complex assembly; IEA:Ensembl.
DR   GO; GO:1904044; P:response to aldosterone; IEA:Ensembl.
DR   GO; GO:0010332; P:response to gamma radiation; IEA:Ensembl.
DR   GO; GO:0023019; P:signal transduction involved in regulation of gene expression; IEA:Ensembl.
DR   GO; GO:0006366; P:transcription from RNA polymerase II promoter; TAS:ProtInc.
DR   GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; IEA:Ensembl.
DR   CDD; cd00027; BRCT; 1.
DR   Gene3D; 1.20.142.10; -; 1.
DR   Gene3D; 2.20.140.10; -; 1.
DR   Gene3D; 3.30.1740.10; -; 2.
DR   Gene3D; 3.40.50.10190; -; 1.
DR   InterPro; IPR001357; BRCT_dom.
DR   InterPro; IPR012982; PADR1.
DR   InterPro; IPR008288; PARP.
DR   InterPro; IPR012317; Poly(ADP-ribose)pol_cat_dom.
DR   InterPro; IPR004102; Poly(ADP-ribose)pol_reg_dom.
DR   InterPro; IPR008893; WGR_domain.
DR   InterPro; IPR001510; Znf_PARP.
DR   Pfam; PF00533; BRCT; 1.
DR   Pfam; PF08063; PADR1; 1.
DR   Pfam; PF00644; PARP; 1.
DR   Pfam; PF02877; PARP_reg; 1.
DR   Pfam; PF05406; WGR; 1.
DR   Pfam; PF00645; zf-PARP; 2.
DR   PIRSF; PIRSF000489; NAD_ADPRT; 1.
DR   SMART; SM00292; BRCT; 1.
DR   SMART; SM01335; PADR1; 1.
DR   SMART; SM00773; WGR; 1.
DR   SMART; SM01336; zf-PARP; 2.
DR   SUPFAM; SSF142921; SSF142921; 1.
DR   SUPFAM; SSF47587; SSF47587; 1.
DR   SUPFAM; SSF52113; SSF52113; 1.
DR   PROSITE; PS50172; BRCT; 1.
DR   PROSITE; PS51060; PARP_ALPHA_HD; 1.
DR   PROSITE; PS51059; PARP_CATALYTIC; 1.
DR   PROSITE; PS00347; PARP_ZN_FINGER_1; 2.
DR   PROSITE; PS50064; PARP_ZN_FINGER_2; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; ADP-ribosylation; Complete proteome;
KW   Direct protein sequencing; DNA damage; DNA repair; DNA-binding;
KW   Glycosyltransferase; Isopeptide bond; Metal-binding; NAD; Nucleus;
KW   Phosphoprotein; Polymorphism; Reference proteome; Repeat;
KW   Transcription; Transcription regulation; Transferase; Ubl conjugation;
KW   Zinc; Zinc-finger.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:22814378,
FT                                ECO:0000269|Ref.12}.
FT   CHAIN         2   1014       Poly [ADP-ribose] polymerase 1.
FT                                /FTId=PRO_0000211320.
FT   DOMAIN      385    476       BRCT. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00033}.
FT   DOMAIN      662    779       PARP alpha-helical. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00398}.
FT   DOMAIN      788   1014       PARP catalytic. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00397}.
FT   DNA_BIND      2    372
FT   ZN_FING       9     93       PARP-type 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00264}.
FT   ZN_FING     113    203       PARP-type 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00264}.
FT   REGION      373    524       Automodification domain.
FT   MOTIF       207    209       Nuclear localization signal.
FT                                {ECO:0000269|PubMed:1505517}.
FT   MOTIF       221    226       Nuclear localization signal.
FT                                {ECO:0000269|PubMed:1505517}.
FT   MOD_RES       2      2       N-acetylalanine.
FT                                {ECO:0000244|PubMed:22814378,
FT                                ECO:0000269|Ref.12}.
FT   MOD_RES      41     41       Phosphoserine.
FT                                {ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES      97     97       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     105    105       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     131    131       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     177    177       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     179    179       Phosphoserine.
FT                                {ECO:0000244|PubMed:17525332,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     185    185       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     274    274       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     277    277       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     364    364       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     368    368       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     407    407       PolyADP-ribosyl glutamic acid.
FT                                {ECO:0000255}.
FT   MOD_RES     413    413       PolyADP-ribosyl glutamic acid.
FT                                {ECO:0000255}.
FT   MOD_RES     435    435       PolyADP-ribosyl glutamic acid.
FT                                {ECO:0000255}.
FT   MOD_RES     437    437       PolyADP-ribosyl glutamic acid.
FT                                {ECO:0000255}.
FT   MOD_RES     444    444       PolyADP-ribosyl glutamic acid.
FT                                {ECO:0000255}.
FT   MOD_RES     445    445       PolyADP-ribosyl glutamic acid.
FT                                {ECO:0000255}.
FT   MOD_RES     448    448       PolyADP-ribosyl glutamic acid.
FT                                {ECO:0000255}.
FT   MOD_RES     456    456       PolyADP-ribosyl glutamic acid.
FT                                {ECO:0000255}.
FT   MOD_RES     471    471       PolyADP-ribosyl glutamic acid.
FT                                {ECO:0000255}.
FT   MOD_RES     484    484       PolyADP-ribosyl glutamic acid.
FT                                {ECO:0000255}.
FT   MOD_RES     488    488       PolyADP-ribosyl glutamic acid.
FT                                {ECO:0000255}.
FT   MOD_RES     491    491       PolyADP-ribosyl glutamic acid.
FT                                {ECO:0000255}.
FT   MOD_RES     499    499       ADP-ribosylserine.
FT                                {ECO:0000269|PubMed:28190768}.
FT   MOD_RES     507    507       ADP-ribosylserine.
FT                                {ECO:0000269|PubMed:28190768}.
FT   MOD_RES     513    513       PolyADP-ribosyl glutamic acid.
FT                                {ECO:0000255}.
FT   MOD_RES     514    514       PolyADP-ribosyl glutamic acid.
FT                                {ECO:0000255}.
FT   MOD_RES     519    519       ADP-ribosylserine.
FT                                {ECO:0000269|PubMed:28190768}.
FT   MOD_RES     520    520       PolyADP-ribosyl glutamic acid.
FT                                {ECO:0000255}.
FT   MOD_RES     600    600       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     621    621       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     782    782       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     786    786       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   CROSSLNK    203    203       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO1).
FT                                {ECO:0000244|PubMed:25114211}.
FT   CROSSLNK    203    203       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:25772364}.
FT   CROSSLNK    467    467       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:25772364}.
FT   CROSSLNK    486    486       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO1).
FT                                {ECO:0000244|PubMed:25114211}.
FT   CROSSLNK    486    486       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:25114211,
FT                                ECO:0000244|PubMed:25218447,
FT                                ECO:0000244|PubMed:25772364}.
FT   CROSSLNK    512    512       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:25218447,
FT                                ECO:0000244|PubMed:25755297,
FT                                ECO:0000244|PubMed:25772364}.
FT   CROSSLNK    748    748       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO1).
FT                                {ECO:0000244|PubMed:25114211}.
FT   CROSSLNK    748    748       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:25218447}.
FT   VARIANT      54     54       F -> L (in dbSNP:rs3738708).
FT                                /FTId=VAR_050460.
FT   VARIANT     188    188       A -> T (in dbSNP:rs1805409).
FT                                {ECO:0000269|Ref.5}.
FT                                /FTId=VAR_014714.
FT   VARIANT     334    334       V -> I (in dbSNP:rs3219057).
FT                                {ECO:0000269|Ref.5}.
FT                                /FTId=VAR_019171.
FT   VARIANT     377    377       P -> S (in dbSNP:rs2230484).
FT                                /FTId=VAR_050461.
FT   VARIANT     383    383       S -> Y (in dbSNP:rs3219062).
FT                                {ECO:0000269|Ref.5}.
FT                                /FTId=VAR_019172.
FT   VARIANT     488    488       E -> V (in a breast cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_035852.
FT   VARIANT     762    762       V -> A (in dbSNP:rs1136410).
FT                                {ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|Ref.5}.
FT                                /FTId=VAR_014715.
FT   VARIANT     940    940       K -> R (in dbSNP:rs3219145).
FT                                {ECO:0000269|PubMed:2891139,
FT                                ECO:0000269|Ref.5}.
FT                                /FTId=VAR_019173.
FT   MUTAGEN     499    499       S->A: Abolishes automodification on
FT                                serine following interaction with HPF1;
FT                                when associated with A-507 and A-519.
FT                                {ECO:0000269|PubMed:28190768}.
FT   MUTAGEN     507    507       S->A: Abolishes automodification on
FT                                serine following interaction with HPF1;
FT                                when associated with A-499 and A-519.
FT                                {ECO:0000269|PubMed:28190768}.
FT   MUTAGEN     519    519       S->A: Abolishes automodification on
FT                                serine following interaction with HPF1;
FT                                when associated with A-499 and A-507.
FT                                {ECO:0000269|PubMed:28190768}.
FT   MUTAGEN     797    797       L->P: 1.5% of wild-type activity.
FT   MUTAGEN     868    868       N->S: 4% of wild-type activity.
FT   MUTAGEN     890    890       M->V: <0.5% of wild-type activity.
FT   MUTAGEN     893    893       K->I: Abolishes enzymatic activity.
FT   MUTAGEN     897    897       F->S: 10% of wild-type activity.
FT   MUTAGEN     899    899       D->N: 0.6% of wild-type activity.
FT   MUTAGEN     908    908       C->R: <0.5% of wild-type activity.
FT   MUTAGEN     926    926       L->F: 1.5% of wild-type activity.
FT   MUTAGEN     986    986       Y->H: 14% of wild-type activity and
FT                                increased branching 15-fold.
FT   MUTAGEN     988    988       E->K: 1.25% of wild-type activity; only
FT                                monomers are added.
FT   MUTAGEN    1003   1003       L->P: 1.5% of wild-type activity.
FT   CONFLICT     17     17       G -> E (in Ref. 2; AAB59447).
FT                                {ECO:0000305}.
FT   CONFLICT     70     70       E -> Q (in Ref. 1; AAA60137).
FT                                {ECO:0000305}.
FT   CONFLICT    212    212       E -> K (in Ref. 2; AAB59447).
FT                                {ECO:0000305}.
FT   CONFLICT    613    613       H -> Q (in Ref. 3; AAA60155).
FT                                {ECO:0000305}.
FT   CONFLICT    827    827       N -> S (in Ref. 3; AAA60155).
FT                                {ECO:0000305}.
FT   CONFLICT    908    908       C -> Y (in Ref. 3; AAA60155).
FT                                {ECO:0000305}.
FT   CONFLICT    980    980       N -> I (in Ref. 3; AAA60155).
FT                                {ECO:0000305}.
FT   TURN          2      5       {ECO:0000244|PDB:2L30}.
FT   STRAND        8     13       {ECO:0000244|PDB:3OD8}.
FT   STRAND       15     17       {ECO:0000244|PDB:3OD8}.
FT   TURN         22     24       {ECO:0000244|PDB:3OD8}.
FT   STRAND       25     27       {ECO:0000244|PDB:2L30}.
FT   STRAND       32     40       {ECO:0000244|PDB:3OD8}.
FT   STRAND       42     53       {ECO:0000244|PDB:3OD8}.
FT   HELIX        54     59       {ECO:0000244|PDB:3OD8}.
FT   HELIX        67     70       {ECO:0000244|PDB:3OD8}.
FT   HELIX        74     76       {ECO:0000244|PDB:3OD8}.
FT   HELIX        79     90       {ECO:0000244|PDB:3OD8}.
FT   STRAND      102    105       {ECO:0000244|PDB:2N8A}.
FT   STRAND      113    117       {ECO:0000244|PDB:3ODC}.
FT   STRAND      119    121       {ECO:0000244|PDB:3ODC}.
FT   TURN        126    128       {ECO:0000244|PDB:3ODC}.
FT   STRAND      137    145       {ECO:0000244|PDB:3ODC}.
FT   STRAND      148    158       {ECO:0000244|PDB:3ODC}.
FT   HELIX       160    165       {ECO:0000244|PDB:3ODC}.
FT   HELIX       167    170       {ECO:0000244|PDB:3ODC}.
FT   TURN        174    176       {ECO:0000244|PDB:3ODC}.
FT   HELIX       177    180       {ECO:0000244|PDB:3ODC}.
FT   HELIX       184    186       {ECO:0000244|PDB:3ODC}.
FT   HELIX       189    198       {ECO:0000244|PDB:3ODC}.
FT   TURN        204    206       {ECO:0000244|PDB:2L31}.
FT   STRAND      209    211       {ECO:0000244|PDB:2N8A}.
FT   HELIX       226    255       {ECO:0000244|PDB:2RIQ}.
FT   HELIX       258    267       {ECO:0000244|PDB:2RIQ}.
FT   TURN        273    275       {ECO:0000244|PDB:2JVN}.
FT   HELIX       276    289       {ECO:0000244|PDB:2RIQ}.
FT   TURN        296    298       {ECO:0000244|PDB:2RIQ}.
FT   STRAND      302    305       {ECO:0000244|PDB:2RIQ}.
FT   STRAND      308    311       {ECO:0000244|PDB:2RIQ}.
FT   STRAND      314    316       {ECO:0000244|PDB:2RIQ}.
FT   STRAND      324    327       {ECO:0000244|PDB:2RIQ}.
FT   HELIX       337    340       {ECO:0000244|PDB:2RIQ}.
FT   HELIX       342    347       {ECO:0000244|PDB:2RIQ}.
FT   STRAND      389    392       {ECO:0000244|PDB:2COK}.
FT   STRAND      394    397       {ECO:0000244|PDB:2COK}.
FT   HELIX       405    414       {ECO:0000244|PDB:2COK}.
FT   STRAND      418    421       {ECO:0000244|PDB:2COK}.
FT   STRAND      427    430       {ECO:0000244|PDB:2COK}.
FT   HELIX       433    438       {ECO:0000244|PDB:2COK}.
FT   HELIX       441    448       {ECO:0000244|PDB:2COK}.
FT   HELIX       457    463       {ECO:0000244|PDB:2COK}.
FT   HELIX       469    475       {ECO:0000244|PDB:2COK}.
FT   HELIX       535    537       {ECO:0000244|PDB:4DQY}.
FT   TURN        540    542       {ECO:0000244|PDB:4DQY}.
FT   STRAND      543    545       {ECO:0000244|PDB:2CR9}.
FT   STRAND      551    560       {ECO:0000244|PDB:4DQY}.
FT   TURN        562    564       {ECO:0000244|PDB:4DQY}.
FT   STRAND      567    573       {ECO:0000244|PDB:4DQY}.
FT   TURN        578    581       {ECO:0000244|PDB:2CR9}.
FT   STRAND      585    591       {ECO:0000244|PDB:4DQY}.
FT   STRAND      597    602       {ECO:0000244|PDB:4DQY}.
FT   HELIX       608    622       {ECO:0000244|PDB:4DQY}.
FT   STRAND      639    641       {ECO:0000244|PDB:4DQY}.
FT   HELIX       667    676       {ECO:0000244|PDB:4ZZZ}.
FT   HELIX       679    688       {ECO:0000244|PDB:4ZZZ}.
FT   TURN        693    695       {ECO:0000244|PDB:4ZZZ}.
FT   HELIX       698    700       {ECO:0000244|PDB:4ZZZ}.
FT   HELIX       703    721       {ECO:0000244|PDB:4ZZZ}.
FT   HELIX       726    739       {ECO:0000244|PDB:4ZZZ}.
FT   STRAND      745    747       {ECO:0000244|PDB:3GJW}.
FT   STRAND      752    754       {ECO:0000244|PDB:1UK0}.
FT   HELIX       755    779       {ECO:0000244|PDB:4ZZZ}.
FT   STRAND      785    787       {ECO:0000244|PDB:4R6E}.
FT   HELIX       789    795       {ECO:0000244|PDB:4ZZZ}.
FT   TURN        796    798       {ECO:0000244|PDB:4GV7}.
FT   STRAND      799    803       {ECO:0000244|PDB:4ZZZ}.
FT   STRAND      806    808       {ECO:0000244|PDB:2RCW}.
FT   HELIX       809    820       {ECO:0000244|PDB:4ZZZ}.
FT   HELIX       824    826       {ECO:0000244|PDB:5WS1}.
FT   STRAND      829    841       {ECO:0000244|PDB:4ZZZ}.
FT   HELIX       844    848       {ECO:0000244|PDB:4ZZZ}.
FT   HELIX       849    853       {ECO:0000244|PDB:4ZZZ}.
FT   STRAND      857    864       {ECO:0000244|PDB:4ZZZ}.
FT   HELIX       866    868       {ECO:0000244|PDB:4ZZZ}.
FT   HELIX       869    875       {ECO:0000244|PDB:4ZZZ}.
FT   STRAND      882    884       {ECO:0000244|PDB:1WOK}.
FT   HELIX       886    888       {ECO:0000244|PDB:4ZZZ}.
FT   STRAND      889    891       {ECO:0000244|PDB:1WOK}.
FT   STRAND      893    900       {ECO:0000244|PDB:4ZZZ}.
FT   HELIX       901    905       {ECO:0000244|PDB:4ZZZ}.
FT   HELIX       906    908       {ECO:0000244|PDB:4ZZZ}.
FT   STRAND      912    914       {ECO:0000244|PDB:4R6E}.
FT   STRAND      916    925       {ECO:0000244|PDB:4ZZZ}.
FT   STRAND      928    934       {ECO:0000244|PDB:4ZZZ}.
FT   STRAND      947    950       {ECO:0000244|PDB:4ZZZ}.
FT   STRAND      952    956       {ECO:0000244|PDB:4ZZZ}.
FT   HELIX       958    960       {ECO:0000244|PDB:5WS1}.
FT   STRAND      962    964       {ECO:0000244|PDB:4ZZZ}.
FT   STRAND      967    969       {ECO:0000244|PDB:4ZZZ}.
FT   STRAND      974    976       {ECO:0000244|PDB:4ZZZ}.
FT   STRAND      983    986       {ECO:0000244|PDB:4ZZZ}.
FT   STRAND      988    993       {ECO:0000244|PDB:4ZZZ}.
FT   HELIX       994    996       {ECO:0000244|PDB:4ZZZ}.
FT   STRAND      997   1009       {ECO:0000244|PDB:4ZZZ}.
SQ   SEQUENCE   1014 AA;  113084 MW;  6A5FC01EB91C046B CRC64;
     MAESSDKLYR VEYAKSGRAS CKKCSESIPK DSLRMAIMVQ SPMFDGKVPH WYHFSCFWKV
     GHSIRHPDVE VDGFSELRWD DQQKVKKTAE AGGVTGKGQD GIGSKAEKTL GDFAAEYAKS
     NRSTCKGCME KIEKGQVRLS KKMVDPEKPQ LGMIDRWYHP GCFVKNREEL GFRPEYSASQ
     LKGFSLLATE DKEALKKQLP GVKSEGKRKG DEVDGVDEVA KKKSKKEKDK DSKLEKALKA
     QNDLIWNIKD ELKKVCSTND LKELLIFNKQ QVPSGESAIL DRVADGMVFG ALLPCEECSG
     QLVFKSDAYY CTGDVTAWTK CMVKTQTPNR KEWVTPKEFR EISYLKKLKV KKQDRIFPPE
     TSASVAATPP PSTASAPAAV NSSASADKPL SNMKILTLGK LSRNKDEVKA MIEKLGGKLT
     GTANKASLCI STKKEVEKMN KKMEEVKEAN IRVVSEDFLQ DVSASTKSLQ ELFLAHILSP
     WGAEVKAEPV EVVAPRGKSG AALSKKSKGQ VKEEGINKSE KRMKLTLKGG AAVDPDSGLE
     HSAHVLEKGG KVFSATLGLV DIVKGTNSYY KLQLLEDDKE NRYWIFRSWG RVGTVIGSNK
     LEQMPSKEDA IEHFMKLYEE KTGNAWHSKN FTKYPKKFYP LEIDYGQDEE AVKKLTVNPG
     TKSKLPKPVQ DLIKMIFDVE SMKKAMVEYE IDLQKMPLGK LSKRQIQAAY SILSEVQQAV
     SQGSSDSQIL DLSNRFYTLI PHDFGMKKPP LLNNADSVQA KVEMLDNLLD IEVAYSLLRG
     GSDDSSKDPI DVNYEKLKTD IKVVDRDSEE AEIIRKYVKN THATTHNAYD LEVIDIFKIE
     REGECQRYKP FKQLHNRRLL WHGSRTTNFA GILSQGLRIA PPEAPVTGYM FGKGIYFADM
     VSKSANYCHT SQGDPIGLIL LGEVALGNMY ELKHASHISK LPKGKHSVKG LGKTTPDPSA
     NISLDGVDVP LGTGISSGVN DTSLLYNEYI VYDIAQVNLK YLLKLKFNFK TSLW
//
